The Netherlands Cancer Institute is well-represented at ESMO 2023 in Madrid

19-10-2023

The annual congress of the European Society for Medical Oncology (ESMO) takes place in Madrid from October 20 to 24. ESMO is the leading professional organization for medical oncology, attended annually by 25,000 oncology professionals from over 160 countries. Key questions and developments in cancer research are addressed here. The Netherlands Cancer Institute is well-represented. Just like last year, they present some exciting and groundbreaking research results on the highest podiums. The European Oncology Nursing Society (EONS) takes place simultaneously. Here, too, the NKI is represented by a nurse practitioner. Some highlights:

CheckMate Study Combination Therapy in Bladder Cancer

For 40 years, chemotherapy has been the standard treatment for bladder cancer patients who can tolerate this medicine. However, the results were limited, and lasting results were rare. Two groundbreaking phase-3 clinical studies have recently focused on a new form of treatment. They investigated the effects of combining immunotherapy and chemotherapy. Internist-oncologist Michiel van der Heijden is involved in both studies. On October 22, he will present the results of one of the studies.

Kaiku App

Nurse Practitioner Judith Lijnsvelt will present the results of the efficacy of her immunotherapy module, part of the Kaiku app. This module allows patients to fill in a survey about potential side effects during treatment. Based on the data provided by the patient, the app can provide advice for mild symptoms. If a patient enters something that requires immediate action, their nurse practitioner or physician will receive a notification. Messages can also be sent through the app. The app offers a new way of digital support during treatment. The usability of the app has been examined, as well as the effect of factors such as age, gender, and the stage of the condition. Judith will present her findings on October 22.

ICRA Study

In the ICRA study, patients with advanced bladder cancer were treated with a combination of chemotherapy and immunotherapy to confirm that these agents together could play a role in eliciting an immune response against the tumor. This study examines the role of the checkpoint inhibitor anti-CTLA4 in the changing therapeutic landscape of metastatic bladder cancer. Medical researcher Sarah Einerhand will present the results of this research on October 22.

N20PCT Study Personalized Cell Product

On October 23, medical researcher Jessica Borgers will present the first results of the N20PTC study, a phase I cell therapy study for patients with metastatic skin cancer. In collaboration with BioNTech and the NKI BioTherapeutics Unit (BTU), a fully personalized cell product has been developed targeting neoantigens: changing proteins on the tumor cells that have arisen due to DNA mutations and can be recognized by the patient's immune system. The outcomes of the first patients treated with this unique, personalized cell product at the NKI will be presented at ESMO.

Overview of all ESMO presentations

Fri. 20.10 16:00	J. Haanen: How to build your own lab and research group in academia	Young Oncologist session
Fri. 20.10 16:15	W. Van Houdt: When can we cure patients with metastatic sarcoma?	Challenge your Expert
Sat. 21.10 09:05	P. Baas: Biomarker-selected therapy: Progress or delusion?	Special Symposium
Sat. 21.10 09:20	S. Einerhand: ICRA: efficacy of paclitaxel with tremelimumab +/- durvalumab in metastatic urothelial carcinoma after progression on platinum chemotherapy and anti-PD-(L)1	Proffered Paper Session
Sat. 21.10 10:20	D. Van de Wal: Fear, anxiety and depression in gastrointestinal stromal tumor (GIST) patients in the Netherlands: data from a cross-sectional multicenter study	Presentation #1914MO Mini Oral session
Sat 21.10 10:30	G. Sonke: How often and to which extent does the E-E gap seriously affect treatment outcome in daily practice?	Special session
Sat. 21.10 15:35	C. Blank: How to personalise neoadjuvant immunotherapy	Educational session
Sat. 21.10 16:30	M. Chalabi: Clinical data of genomic subtypes of mCRC (MSI, BRAF V600, HER2, KRAS G12C, NTRK)	Educational session
Sun. 22.10 10:15	J. Lijnsvelt: CN3 - Patient adherence to digital patient-reported outcome monitoring (PROM) in cancer immunotherapies	EONS session
Sun. 22.10 15:05	M. Tesselaar: Perioperative considerations and management of localised disease	Special Symposium
Sun. 22.10 15:15	Y. Verschoor: Neoadjuvant nivolumab plus relatlimab (anti-LAG3) in locally advanced MMR-deficient colon cancers: the NICHE-3 study	Presentation # LBA31 Mini Oral session
Sun. 22.10 16:42	M. Van Der Heijden: Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: results from the phase 3 CheckMate 901 trial	Proffered Paper session
Sun. 22.10 19:15	W. Van Houdt: Multidisciplinary management of non-melanoma skin cancer: Surgical Perspective	Industry Satellite Symposium
Mon. 23.10 10:35	R. Beets-Tan: How to perform an accurate staging?	Multidisciplinary session
Mon. 23.10 10:45	J. Borgers: TC-001: A phase I study to test safety and efficacy of BNT221, a non-engineered neoantigen-specific T cell product, in patients with advanced or metastatic melanoma	Proffered Paper Session
Mon. 23.10 11:05	J. Jonkers: Understanding and overcoming resistance to PARP inhibitors: What is the way forward?	Multidisciplinary session
Mon. 23.10 15:05	L. Van De Poll-Franse: Quality of life in IO-treated long-term survivors	Special symposium
Mon. 23.10 15:35	W. Van Houdt: How to treat bone, soft tissue and GIST patients with a hereditary predisposition: A medical oncologist’s perspective	Educational session
Mon. 23.10 16:35	S. Janssen: The high burden of long-term and late health-related problems among adolescent and young adult cancer survivors: Results of the SURVAYA study	Presentation #1693MO Mini Oral Session
Mon. 23.10 16:40	S. Janssen: Socio-economic consequences among adolescent and young adult cancer patients: A European perspective	Presentation #1694MO Mini Oral session
Mon 23.10 17:30	J. Haanen: BNT211-01: Interim results from a repeat dose escalation study of CLDN6 CAR-T cells manufactured with an automated process ± a CLDN6- encoding CAR-T cell-Amplifying RNA Vaccine (CARVac)	Presentation #LBA35 Mini Oral session

The Netherlands Cancer Institute is well-represented at ESMO 2023 in Madrid

This site uses cookies